The currently preferred staging system in AL amyloidosis is the Mayo Amyloidosis Staging System that utilizes the aforementioned biomarkers cTNT, NT-proBNP and dFLC to stratify disease severity in patients with AL (Table 1) [77]. Here, NPPB is linked to AL amyloidosis.